Scientist / Associate Scientist, Cancer Immunotherapy
Fate Therapeutics is currently seeking a skilled and motivated cell biologist to support the company’s Cancer Immunotherapy programs. The successful candidate will join a multidisciplinary team pursuing the development and characterization of next generation engineered T and CAR-T cells from gene edited induced pluripotent stem cells (iPSCs) for the development of off-the-shelf immunotherapies. The candidate must have good knowledge of cell biology with emphasis on hematopoiesis and extensive experience with tissue culture, specifically with primary cells derived from blood, embryonic stem cells (ESCs), iPSCs, and stromal cells. The candidate will perform, optimize and analyze experiments involving the in vitro differentiation of iPSC towards the T lymphoid lineage. Primary responsibilities will include the derivation of novel platforms to generate functional subsets of T lymphocytes from iPSCs, including the planning and execution of functional assays and the support of downstream application groups. This position will require independent research as well as coordination with the molecular biology, cellular engineering and process development divisions. This is a full-time position and is located at our corporate headquarters in San Diego, CA.
- Support the development of novel protocols and employment of unique strategies
- Derivation of engineered T lymphocytes
- Immune cells functional assay, e.g., proliferation, activation/stimulation, cytokine release, in vitro and in vivo killing assays
- Stromal cell culture, maintenance and cryopreservation
- iPSC culture and maintenance and iPSC hematopoietic differentiation
- Cellular characterization utilizing flow cytometry, microscopy, automated cell counting, immunofluorescence and molecular analysis including RNA-seq.
- FACS sorting on BD instrumentation and enrichment/depletion on Miltenyi instrumentation
- Flow cytometry data analysis using FlowJo software
- Ordering and maintaining stocks of lab reagents and samples
- B.S. degree + 8 years lab experience, M.S. degree + 5 years relevant lab experience or PhD in Cell Biology, Developmental Biology, Immunology or other related fields.
- Prior (min 3-5 years) experience and extensive knowledge in aseptic cell culture techniques
- Prior experience with flow cytometry data acquisition and analysis
- Excellent communication, record keeping and data analysis skills
- Experience with CAR-T cells is a plus
- Hands on experience with ESC and iPSC in vitro differentiation or primary hematopoietic cell culture is desirable
- Self-motivation, excellent time management, organizational, analytical and problem-solving skills.
- Ability to take direction and work independently, but with strong team orientation and excellent written and oral communication skills
Working Conditions and Physical Requirements
- Will require working with blood and cell lines of human and animal origin
- Will require working with hazardous materials
- 100% on-site work at corporate headquarters in San Diego, CA
- Evening and weekend work as necessary
The preceding job description indicates the general nature and level of work performed by employees within this classification. Additional and incidental duties related to the primary duties may be required from time to time.
For consideration send cover letter and resume to: firstname.lastname@example.org and reference job code 210CC.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company is pioneering the development of off-the-shelf cell therapies using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline is comprised of FATE-NK100, a donor-derived natural killer (NK) cell cancer immunotherapy that is currently being evaluated in three Phase 1 clinical trials, as well as iPSC-derived NK cell and T-cell immunotherapies, with a focus on developing augmented cell products intended to synergize with checkpoint inhibitor and monoclonal antibody therapies and to target tumor-specific antigens. The Company’s immuno-regulatory pipeline includes ProTmune™, a next-generation donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.